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Abstract There are seven known subtilisin/kexin-like propro- 
rein convertases responsible for the processing of numerous 
precursors at either pairs or specific single basic residues. Three 
members, PACEA, PC4 and PC5, exhibit alternative splicing of 
their RNAs resulting in the generation of multiple isoforms 
differing in their C- or N-terminal segments. In this study we 
t~xamined the biosynthesis, functional activity and cellular 
localization of two of these isoforms, namely the full length 
PACE4-A and the C-terminally truncated PACE4-C which 
lacks 11 amino acids at the end of its chaperone-like P-domain. 
We report the existence of a new isoform, termed PACE4-CS, 
which is a C-terminally shortened version of PACE4-C. Cellular 
expression results demonstrated that PACE4-A codes for a 
functional secretable enzyme capable of cleaving pro7B2 into 
7B2. In contrast, PACE4-CS is not secreted since it remains in 
the endoplasmic reticulum as an inactive zymogen form, thereby 
emphasizing the importance of the integrity of the P-domain. 
Vlicrosequencing of the intracellular PACE4-CS protein in two 
cell lines revealed that it is proPACE4-CS with an N-terminal 
trimming reminiscent of the action of a dipeptidyipeptidase 
recognizing the motifs X-Ala and X-Pro. 
t~ey words: PACE4-A; PACE4-C; PACE4-CS; Convertase; 
~lternative splicing; 7B2 
• Introduction 
Processing of proproteins and prohormones at either single 
• ,r pairs of basic residues is a general mechanism to generate 
t,ioactive proteins and peptides from inactive precursors [1,2]. 
"he subtilisin/kexin-like proteinases responsible for such in- 
t racellular cleavages have recently been described and are 
alled 'proprotein convertases' (PCs). So far, seven members 
,,f this family have been identified: furin, PC1, PC2, PC4, 
I'ACE4, PC5 and PC7 (for reviews see [14]). All of these 
I'Cs exhibit an N-terminal signal peptide, followed by a 
i,ro-segment, a catalytic domain, a P-domain and an en- 
zyme-specific C-terminal segment [5]. Variant cDNA struc- 
tures, possibly arising from alternative gene splicing, have 
!,een reported for PC4 [6,7], PC5 [8] and PACE4 [9,10]. In 
the case of PC5, the isoform PC5-A is directed to secretory 
!ranules while PC5-B localizes to the trans Golgi network 
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[bbreviations: VV, vaccinia virus; PC, precursor convertase; RT- 
|'CR, reverse transcriptase polymerase chain reaction 
(TGN) [11]. For human PACE4 four different isoforms have 
so far been reported; they are named PACE4-A (full length), 
PACE4-B (also known as PACE4.1), PACE4-C and PACE4- 
D [9,10]. Furthermore, as compared to human PACE4-A [9], 
the rat and mouse homologues [12,13] exhibit an extra Leu 
residue close to the predicted signal peptidase cleavage site 
and additionally show three deletions within the signal pep- 
tide, the N-terminal of the catalytic domain and the C-ter- 
minal segment which follows the conserved P-domain. From 
the reported importance of the pro-segment acting as an in- 
tramolecular chaperone in subtilisin-like nzymes [14], it was 
suggested that PACE4-D would code for an inactive enzyme 
[10]. Similarly, as the integrity of the P-domain has been re- 
ported to be critical for the activity of yeast kexin [15] and 
mouse furin [16], it was also predicted that PACE4-B, which 
lacks the P-domain, would be inactive [9]. In contrast, 
PACE4-C (652 aa), which is truncated at the C-terminus com- 
pared to PACE4-A (969 aa), has a distinct sequence at the end 
of the P-domain, resulting in a shorter form in which the 32 
amino acids following Gly 620 are different. While the C-ter- 
minal border of the P-domain has been suggested to be close 
to Gly 631 [5,15,16], its exact site is not known with certainty 
and could be convertase-dependent. Therefore, it was sug- 
gested that PACE4-C could code for an active convertase 
[10]. Furthermore, it was reported that PACE4-C is expressed 
in a tissue-specific manner, based on RT-PCR [17] and im- 
munocytochemical [18] criteria. 
In this work, we isolated a fifth isoform called PACE4-CS 
(shortened form of PACE4-C), which led us to address the 
question of the integrity of the P-domain, the tissue distribu- 
tion of the PACE4 isoforms and to suggest hat PACE4-A is 
the only active proteinase of the isoforms so far known. 
2. Materials and methods 
2.1. Cellular expression of PA CE4 isoforms 
The mRNA expression of PACE4 isoforms was analyzed by RT- 
PCR on 5 lag of total RNA [19] isolated from established cell lines 
including: Caco2 (colon carcinoma, human), LoVo (colon adeno- 
carcinoma, human), HepG2 (hepatocellular carcinoma, human), 
and SKNM (neuroepithelioma, human). The sense oligonucleotides 
used were the general PACE4 oligonucleotides: oligo II: TT- 
CATGACTGTCCACTGCTGGGGAG, oligo VI: GGGACCT- 
CAGTCTCTGCCCCCATG; and the PACE4-C/CS-specific oligo 
IV: CCTGGACTAAAACACGT. The antisense oligonucleotides 
were either the PACE4-A-specific oligo I: CAGACAGTACATTTCT- 
CA; or the PACE4-C/CS-specific oligo III: CTACTGGAGATACA- 
GAACCGAC, and the [HindlIl]-containing oligo V: [AAGCTT]- 
GCGGGAGCTGAGAGATCCAGCTCTGGAC. The 30 cycle PCR 
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reactions were performed at an annealing temperature of 58°C for 
PACE4-A-specific reactions (oligo pair II/I) and for PACE4-C/CS- 
specific PCRs at either 50°C (oligo pair II/III) or 55°C for the pair 
VI/V and for the nested PCR using the pair IV/Ill. 
2.2. Vaccinia virus (VV) expression of PACE4-A and PACE4-CS 
The RT-PCR product of a PACE4-C-specific sequence using the 
oligo VI/V pair allowed the isolation of a 770 bp PACE4-C-Iike frag- 
ment. Transfer to the PCRTMII vector and sequencing revealed that 
this segment is an alternatively spliced product of PACE4-C called 
PACE4-CS (Fig. 2). This allowed us to construct a PACE4-CS cDNA 
by ligation of the 5' NcoI and 3' HindIII digested PCR product (745 
bp) into the original PMJ601 VV transfer vector containing the full 
length PACE4-A cDNA digested with the same enzymes [20]. The 
isolation of the recombinant VV was obtained as previously described 
[21]. Green monkey kidney epithelial BSC40 cells or mouse cortico- 
troph AtT20 cells were infected with 4 pfu/cell of either VV :hPACE4- 
A, VV:hPACE4-CS or VV:wild type (VV:WT) [21]. Following over- 
night growth, the cells were washed and then pulse-labeled with 
[3~S]methionine, [aH]tyrosine or [3H]valine for 4 h, as previously de- 
scribed [20,21]. The media and cell extracts were then purified on a 
lentil lectin column (Pharmacia) and analyzed by autoradiography of 
an SDS-PAGE separation. The identified PACE4-CS (77 kDa) 
[3H]Tyr- and [3H]Val-labeled bands were then excised and the under- 
lying protein microsequenced on an Applied Biosystem model 470A 
sequenator, as previously described [20-22]. 
2.3. Bioactivity of PACE4 isoforms 
The enzymatic activity of PACE4-A or PACE4-CS was gauged by 
its capacity to process the neuroendocrine precursor pro7B2 [20]. Ac- 
cordingly, BSC40 cells infected with 2 pfu/cell of VV:m7B2 were co- 
infected with 4 pfu/cell of either VV:PACE4-A, VV:PACE4-CS or 
VV:wild type. Following overnight growth, the cells were pulse-la- 
beled for 30 min (P30) with [aSS]methionine and then chased with 
cold methionine for 60 min (C60). The cell extracts and media were 
immunoprecipitated with a 7B2-specific antibody and the precipitates 
analyzed by SDS-PAGE as described elsewhere [20]. 
3. Resu l ts  
3.1. Cellular expression of  PACE4 isoforms 
Previous results using a general PACE4 probe recognizing 
all isoforms demonstrated the widespread tissue and cellular 
mRNA expression of PACE4 [3,9,12,13,17,23]. Aside from the 
major 4.4 kb transcript, a 3.9 kb mRNA was also detected in 
some rat tissues such as the jejunum, duodenum and kidney 
[3], suggesting the presence of alternatively spliced mRNA 
forms of PACE4. Recent reports of Tsuji et al. [10,17] suggest 
that an alternatively spliced human PACE4-C isoform can be 
isolated from human placenta. However, none of these iso- 
forms could be detected by screening mouse liver, kidney or 
brain cDNA libraries [13]. In order to probe for the specific 
expression of the PACE4-A and PACE4-C isoforms, we first 
attempted to perform Northern blots on cell lines and rat 
tissues with human PACE4-A and PACE4-C-specific probes 
obtained by PCR using the oligo pairs II/I and IV/I l l ,  respec- 
tively (Fig. IA). Although similar results to those obtained in 
[3] were found for PACE4-A expression, we could not detect 
PACE4-C-specific mRNAs in the tissues or cells analyzed in 
[3] (not shown). Therefore, we opted for the use of RT-PCR 
as an alternative and more sensitive approach for the detec- 
tion of PACE4-C-specific mRNA.  Accordingly, two consecu- 
tive PCR amplifications were needed in order to detect 
PACE4-C-like transcripts. In the first PCR, no visible ampli- 
fication product was obtained with the oligo pair II/III. How- 
ever, nested PCR of an aliquot of this first amplification using 
the oligo pair IV/I l l  allowed the detection of PACE4-C-like 
expression in the human cell lines Caco2, LoVo, HepG2 but 
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Fig. 1. Tissue and cell expression of PACE4. A: Diagrammatic rep- 
resentation of human hPACE4-A and hPACE4-C DNA structures 
including the signal peptide (SP), pro-segment (PRO), catalytic do- 
main (CAT), P-domain (P) and C-terminal Cys-rich domain (CYS). 
The 5' and 3' non-coding segments are represented by a horizontal 
line. The positions of the oligonucleotides u ed in the RT-PCR am- 
plifications are shown. The putative Gly TM at the C-terminal end of 
the P-domain as well as the Gly 62° where splicing caused the genera- 
tion of PACFA-C and PACE4-CS, are emphasized. B: RT-PCR of 
PACE4-C in the human cell lines SKNM, HepG2, LoVo and 
Caco2. The first RT-PCR done with the oligo pair II/III (30 cycles) 
was followed by a nested PCR with the pair IV/III (30 cycles). C: 
RT-PCR of PACE4-A done with the oligo pair II/I (30 cycles). D: 
RT-PCR of PACE4-CS done on cell lines and human pituitary 
RNA with the oligo pair VI/V (35 cycles)• 
not in SKNM cells (Fig. 1A,B). In contrast, PACE4-A expres- 
sion was easily detected by RT-PCR using the single oligo 
pair II/I (Fig. 1A,C). This result suggests that in the cells 
analyzed, PACE4-A transcripts are much more abundant 
than those of PACE4-C. 
In order to obtain a construction of the full length PACE4- 
C, it was necessary to amplify the variant 3' end using the 
oligo pair VI/V starting from either HepG2 or Caco2 cells 
(Fig. 1A,D). With this pair it was possible to detect the ex- 
pected PACE4-C-Iike product of 770 bp on the first amplifi- 
cation reaction by using 35 cycles of amplification instead of 
the usual 30 (Fig. 1D). In contrast, the same RT-PCR done 
on human pituitary RNA did not yield any product (Fig. 1D). 
To our surprise, the DNA sequence of this PCR product was 
itself a spliced form of PACE4-C, where the gt/ag donor/ac- 
ceptor splice sites were derived from an exon of PACE4-C 
(Fig. 2). Accordingly, this new variant, called PACE4-CS, is 
a 3' shortened version of PACE4-C with a different C-ter- 
minal sequence. Thus, both PACE4-C and PACE4-CS diverge 
from PACE4-A at Gly 62° within the predicted P-domain (Fig. 
2). However, PACE4-C and PACE4-CS are C-terminally ex- 
tended by 32 and 3 amino acids to give proteins composed of 
652 and 623 residues, respectively. Analysis of 11 different 
clonal inserts in PCRTMII (see Section 2) gave the same 
DNA sequence and did not reveal the presence of an authen- 
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I n t ron /Exon  Junct ion  
~14 N P E K Q G 62° K L K E W S L I ~2e 
PACE4-A  CGC AAC CCG GAG AAG CAA GGG AAG TTG AAA GAA TGG AGC CTC ATA 
G ~=° D L E T P V A N ~e 
PACE4-C GGT GAT CTT GAG ACT CCT GTT GCA AAT 
G6z0 
PACE4-CS G~ gat  ctt  gag  act cct  g t t  gca  aat  
End of P -Domain  
L ~2~ Y G I T A E H P Y H T F S A H 643 
PACE4-A  CTG TAT GGCIACA GCA GAG CAC CCG TAC CAC ACC TTC AGT GCC CAT 
Q~2S L T T E E R E P G L K H V F ~43 
PACE4-C  CAA CTG ACC ACA GAA GAG AGG GAA CCT GGA CTA AAA CAC GTG TTC 
N ~:tl L D ~23 • 
PACE4-CS caa c tg  acc aca gaa gag  ~ AAC CTG GAC TAA 
Q644 S R S R M L E L S A P E L E ~sa 969 aa 
PACE4-A  CAG TCC CGC TCG CGG ATG CTG GAG CTC TCA GCC CCA GAG CTG GAG 
R ~44 W Q I E Q E L W ~2 ~ 652 a~ 
PACE4-C CGG TGG CAG ATT  GAA CAA GAG CTT TGG TAA 
! ig. 2. Generation of PACE4-A, PACE4-C and PACE4-CS isoforms by alternative splicing of the human PACE4 gene. The positions of the 
i~tron-exon junction ($) and the end of the P-domain ([) are shown. The small etter notations in PACE4-CS emphasize the splicing of this 
s,~gment atthe canonical gt/ag sites resulting in the production of the PACE4-CS isoform. 
lc  PACE4-C product. This 770 bp product was then digested 
~ith appropriate restriction enzymes (see Section 2) and li- 
~ated to the equivalently digested PACE4-A cDNA, resulting 
i 1 a full length PACE4-CS construct which was used to obtain 
VV:PACE4-CS recombinant. 
., 2. Biosynthetic analysis of  PACE4-A and PACE4-CS 
Cellular expression of PACE4-A and PACE4-CS was ana- 
l~,zed after infection of the constitutively secreting cell line 
BSC40 with either VV:PACE4-A or VV:PACE4-CS and foi- 
l)wed by a 4 h pulse-labeling with [35S]methionine. The la- 
1,eled products could not be immunoprecipitated as PACE4- 
~pecific antibodies are not yet available. As an alternative, 
~nce PACE4 is predicted to be N-glycosylated [9], we used 
~, lentil lectin column [24] to concentrate N-glycosylated pro- 
~ins from cell extracts and media. As shown in Fig. 3, this 
;~chnique revealed that PACE4-CS encodes a non-secretable 
!,rotein (even after very long exposure of the gel, no protein is 
, erected in the medium) migrating with an apparent Mr of 77 
: Da on SDS-PAGE. In contrast, VV:PACE4-A expression 
,~sults in the intracellular labeling of a number of bands mi- 
i:rating with Mr of 160-180 kDa but releasing only the 150 
Da product. Therefore, although PACE4-A is a secretable 
,rotein, PACE4-CS is not detectable in the medium. Further- 
~lore, digestion of the 77 kDa PACE4-CS with either endo- 
lycosidase H or N-glycanase F [25] revealed that this form is 
,ensitive to both enzymes (not shown). In contrast, the se- 
,. feted 150 kDa PACE4-A is only digested by N-glycanase F 
~sulting in a 5 kDa decrease in apparent molecular mass (not 
hown). Therefore, both PACE4-CS and PACE4-A migrate 
vith apparent molecular masses much higher than predicted 
yore their amino acid sequences and this is not primarily due 
:~ carbohydrate attachment, but could in part be due to the 
~'ys-rich domain in PACE4-A, as observed for Drosophila 
l urins [26]. These data suggest hat PACE4-CS is localized 
~vithin a cellular compartment where trimming of carbohy- 
drate chains does not proceed to completion, most likely the 
~:ndoplasmic reticulum itself, whereas PACE4-A can exit the 
,.ell through the constitutive secretory pathway of BSC40 
~ ells. 
In order to unequivocally define the nature of the 77 kDa 
PACE4-CS product, we microsequenced the [3H]Val- and 
['~H]Tyr-labeled proteins obtained from both AtT20 and 
BSC40 cells. The N-terminal sequence of the intracellular 77 
kDa PACE4-CS product reveals a Tyr 7 in AtT20 cells (Fig. 
4A) and a Tyr 67 in BSC40 cells (Fig. 4B). This surprising 
result led us to examine the sequence of valine-labeled 
PACE4-CS from BSC40 cells. The data obtained suggest he 
presence of two chains differing by one amino acid, i.e. of 
sequence Val ~,12,]4 and Val 6'13,15 (Fig. 4C). This interpretation 
is based on the much lower carry-over of radioactivity from 
cycle to cycle obtained for labeled proteins which were se- 
quenced before and after PACE4-CS (not shown). From the 
predicted protein structure of PACE4 [9], these results uggest 
that the 77 kDa sequence starts at either Pro 64 or Pro 65 in 
BSC40 cells and at Pro G4 in AtT20 cells. Furthermore, the 
data demonstrate hat proPACE4-CS is not processed into 
PACE4-CS. 
3.3. Processing of pro7B2 by PACE4-A and PACE4-CS 
In order to demonstrate enzymatic activity of the PACE4 
isoforms, the medium of BSC40 cells overexpressing PACE4- 
A or PACE4-CS was partially purified on a DEAE column as 
reported for PCI [27]. Accordingly, although appreciable ac- 
tivity towards the fluorogenic substrate pGluArgThrLysArg- 
MCA was observed for PACE4-A (Munzer et al., in prepara- 
tion), none was obtained for PACE4-CS (not shown). This 
result is in agreement with the biosynthetic data (Fig. 3) which 
revealed that only PACE4-A could be detected in the medium. 
In order to further probe the intracellular enzymatic activity 
of either PACE4-A or PACE4-CS, we co-expressed these iso- 
forms with pro7B2, a PC2-specific binding protein [20,28,29] 
known to be processed in the TGN by furin-like enzymes 
[20,30]. As shown in Fig. 5, only PACE4-A was able to in- 
crease the intracellular processing of pro7B2 (30 kDa) into 
7B2 (23 kDa), which is then secreted. No increased processing 
over background control (pro7B2/wild-type virus) was ob- 
served when PACE4-CS was co-expressed with pro7B2 (Fig. 
5). In conclusion, our data demonstrate hat PACE4-CS does 
not exhibit intracellular (ex vivo) or extracellular (in vitro) 
enzymatic activity. Accordingly, we suggest that only 
PACE4-A is an enzymatically active convertase. 
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Fig. 3. SDS-PAGE analysis of the biosynthesis of PACE4-A and 
PACE4-CS. BSC40 cells were infected with 4 pfu/cell of either 
VV:WT, VV:PACE4-CS or VV:PACE4-A and then pulse-labeled 
for 240 min (P240) with [35S]methionine. The media and cell ex- 
tracts were then purified on a lentil lectin column and analyzed by 
SDS-PAGE (8% T, 2.7% C). Based on the migration of the molecu- 
lar standards the molecular weights of PACE4-CS (77 kDa) and 
PACE4-A (160-t80 kDa) were estimated. 
4. Discussion 
Tissue-specific processing of inactive precursors into active 
polypeptides i  a general mechanism to generate and regulate 
the level of biological diversity achieved with a given propro- 
tein. The role of the PCs in the generation of such diversity is 
now well accepted and is the subject of intense study aimed at 
defining the specific role of each of the seven known conver- 
tases in this process [1-5]. Another level of diversity can also 
be achieved by alternative splicing of either the proprotein 
substrate or its cognate convertase(s). For example, the differ- 
ential intracellular localization of the two PC5-A and PC5-B 
isoforms is expected to affect the fate of different sets of pre- 
cursors since PC5-B would cleave constitutively secreted pro- 
teins, whereas PC5-A could also process proteins sorted to 
dense-core secretory granules [11]. In a similar fashion, it 
was thought hat the isoforms of PACE4 could also lead to 
different subcellular localizations of the resultant enzymes. 
Indeed, our results clearly show that whereas PACE4-A is 
secreted and active, PACE4-CS is retained intracellularly 
(likely in the ER) as an inactive proPACE4-CS zymogen. 
Therefore, analogous to profurin [31] and proPC1 [21] which 
remain in the endoplasmic reticulum and are not secreted, it is 
likely that the 77 kDa proPACE4-CS undergoes a similar fate. 
What then is the function of a seemingly inactive convertase 
in the ER? One possibility is that it may act as a dominant 
negative and affect the level of active PACE4-A, e.g. by inter- 
fering with its transport through the cellular secretory path- 
way. However, cellular co-expression of PACE4-A and 
PACE4-CS together with pro7B2 did not affect its processing 
to 7B2 by PACE4-A (S. Benjannet and N.G. Seidah, unpub- 
lished results). Therefore, although we still do not know the 
role of the PACE4 isoforms, it is possible that it is an accident 
of genetic noise as a result of evolutionary pressures. 
The P-domain found at the C-terminus of the catalytic seg- 
ment in the PCs is not found in the ancestral bacterial sub- 
tilisins and has been acquired by the eukaryotic PC genes. The 
function of this domain is not well known, but recent data 
suggest hat it may play an important chaperone-like role in 
the folding of the zymogen, hence allowing autocatalytic pro- 
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Fig. 4. Microsequence analysis of PACE4-CS. Radiolabeled 77 kDa 
PACE4-CS was obtained from the cell extracts of AtT20 (A) and 
BSC40 (B,C) cells pulsed for 4 h with either [3H]tyrosine (A,B) or 
[3H]valine (C). The labeled proteins were separated by SDS-PAGE 
(8% T, 2.7% C), and the gel was then sliced (1 mm) and the eluted 
77 kDa proteins were sequenced for 20 cycles. Cycle 0 corresponds 
to a full sequencing cycle performed in the absence of the coupling 
reagent phenylisothiocyanate. Th  numbers above the peaks repre- 
sent he deduced sequence positions. 
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1 ig. 5. Comparative processing of pro7B2 by PACE4-CS and 
1'ACE4-A. BSC40 cells were co-infected with VV:7B2 (2 pfu/cell) 
~nd with 4 pfu/cell of either VV:WT, VV:PACE4-CS or 
~'V:PACE4-A and then pulse-labeled for 30 rain (P30) with 
[ 5S]methionine, followed by a chase of 60 min (C60) in the pres- 
t nce of cold methionine. The media and cell extracts were then im- 
~ mnoprecipitated with a 7B2 antibody [20] and analyzed by SDS- 
PAGE (15% T, 1.3% C). The positions of pro7B2 (30 kDa) and 
B2 (23 kDa) are emphasized. The band above pro7B2 was ob- 
:erved previously [20] and is a non-specific protein which is not se- 
reted. 
,.essing of the proPCs [14-16]. The integrity of this domain is 
,,bviously affected in the PACE4-C/CS isoforms as it lacks at 
east 11 C-terminal amino acids which are replaced by 36 or 3 
:a of different composition, respectively. This may explain 
why proPACE4-CS is not processed to PACE4-CS (Fig. 3), 
rendering the enzyme functionally inactive (Fig. 5). By anal- 
,,gy, we believe that PACE4-C should also code for an inac- 
tive enzyme. 
In certain rat tissues such as the jejunum, duodenum and 
kidney, aside from the major 4.4 kb transcript of PACE4-A, a 
.9 kb mRNA was also detected [3]. However, Northern blot 
,malyses of those same tissues with a PACE4-C/CS-specific 
i)robe did not reveal any labeling of specific transcripts (not 
~ hown), demonstrating that the 3.9 kb form is not PACE4-C/ 
,2S. In agreement with the mouse data of Hosaka et al. [13], 
he  mRNA level of PACE4-C/CS seems to be low compared 
o PACE4-A in all the cell lines and rat tissues examined (Fig. 
). Intriguingly, a recent report suggested that PACE4-C im- 
nunoreactivity could be detected in rat pancreatic [3-cells [18], 
vhich are also known to express PC1 and PC2 [2,32]. Further- 
nore, the authors claim that PACE4-A immunoreactivity was 
mdetectable in pancreatic islets [18]. The peptide antigen used 
o obtain this PACE4-C-specific antibody [18] would not rec- 
)gnize PACE4-CS as these two isoforms differ at their C- 
erminus (Fig. 2). It remains to be seen whether PACE4-CS 
s also expressed in [3-cells, as we did not study the expression 
of PACE4 in the pancreas [3]. However, we believe that the 
PACE4-C/CS isoforms would be functionally inactive and 
hence would not directly participate in the processing of pro- 
proteins in this tissue. 
Using the von Heijne criteria [33], we estimated the best 
predicted signal peptidase cleavage site of human proPACE4 
as ACS+APPPRPVYTNHWAVQV and of rat/mouse 
PACE4 as ACSASLPPPRPVYTNHWAVQV [12,13]. The 
second best predicted site occurs at the AC $ SAPPP sequence. 
Interestingly, if this site was recognized by the signal pepti- 
dase, the N-terminal sequence of human PACE4-CS would 
reveal the absence of either the dipeptide AlaPro (Val 5,a2,14 
and Tyr 6 in BSC40 cells) or SerAla (Val 6'13'1~ in BSC40 cells 
and Tyr 7 in AtT20 cells) (Fig. 4), suggesting an aminodipep- 
tidase activity endogenous to BSC40 and AtT20 cells which 
recognizes these sequences. It is a matter of speculation 
whether at/mouse proPACE4 would also lose its N-terminal 
LeuPro dipeptide. It has been reported that the secretory 
pathway of honeybee, amphibian skin and yeast [34] expresses 
a dipeptidylaminopeptidase with an X-Pro > X-Ala > X-Gly 
specificity, resembling the mammalian dipeptidylpeptidase en- 
zyme. However, the restrictions on the nature of the X-residue 
are not yet clear. It would be informative to pursue this ob- 
servation in the future and identify the putative mammalian 
homologue which could be related to the enzyme responsible 
for the reported stepwise processing of canine gastrin releasing 
peptide at the N-terminal ValPro-LeuPro sequence [34]. 
In conclusion, our data demonstrate hat PACE4-A is likely 
to be the only active form of the PACE4 isoforms so far 
known. This does not exclude the possibility that other 
C-terminal variant forms which retain the integrity of the 
P-domain may turn out to be active enzymes. Thus far, dif- 
ferential splicing of convertase transcripts has resulted in mul- 
tiple active forms only for PC5 where PC5-A and PC5-B were 
demonstrated to be functionally active convertases derived 
from a single PC5 gene [11,20,22]. 
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